All News

The Tufts Center for the Study of Drug Development (CSDD) sees two key trends as increasingly important for pharmaceutical companies to maintain success:

On average, cancer docs in the US would much rather deal with pharma sales reps in person as opposed to online, and drug companies are hiring more reps to support a slew of newly approved oncologic drugs.

The perennial fat got chewed during the first two days at J.P. Morgan’s annual healthcare conference – buy back stock or raise dividends? – and the usual suspects lurked, but newcomers like Walgreens and not-so-pharma companies like Life Technologies packed the presentation halls and corridors,

30 years ago last week, the US Orphan Drug Act came into being, and with it, a door of possibilities opened up for patients with literally thousands of untreated diseases.

Thankfully, the civil war is not a public relations issue for Big Pharma, but the long-term business implications for the Middle East region are cagey.

2013 may be a number associated with the fate of the luckless, but our annual review of the business and policy environment for Big Pharma suggests otherwise-as we near the midway point in the "tween" decade, there is good fortune in store for those with the perspective that comes with the long view.

Industry Forecast 2013, The Search for Safe Harbors

The Securities and Exchange Commission filed charges on Eli Lilly and Co. yesterday for violations of the Foreign Corrupt Practices Act (FCPA) that allege the drug maker’s subsidiaries overseas bribed foreign officials in Russia, China, Brazil and Poland.

A just-published report from the European taskforce trying to help Greece crawl out of its crisis makes clear just how significant a role health reform is supposed to play in restoring health to the economy.

With the general election behind us, the anticipated avalanche of ObamaCare regulations has begun. Last week, it was reported that more than 13,000 pages of rules and regulations have been issued by HHS since Nov. 6th

Hindsight can be a great teacher – but only if you have the self-awareness needed to adapt those learnings to the next business challenge, whose rough edges are by definition almost always “non-recurring.”

Participants in the 23rd Annual NYPF General Assembly last Friday outlined the many challenges facing industry, and the importance of collaboration as a way to move forward.

The National Intelligence Council’s Global Trends Report explains the scenarios in which the next 18 years may play out internationally.

Yesterday Acura Pharmaceuticals launched its new pseudoephedrine-based product Nexafed, an over-the-counter product aimed at deterring abuse of the illicit drug methamphetamine.

The Puzzle Master

The pharmaceutical industry’s global reputation is on the mend, even if some countries – notably China – are more hostile, according to the latest Ipsos Reputation Snapshot for the Pharmaceutical Sector, from the Ipsos Global Reputation Centre.

Price Waterhouse Cooper’s “Pharma 2020: From vision to decision” parses a mix of gloomy and glowing scenarios that reflect the fickle, delicate nature of today’s industry.

Given the amount of activity in the hepatitis C drug development space – as evidenced in PharmExec’s 2013 Pipeline report – patients are scouring the internet for information on the disease, available treatments, and soon to be available treatments.

Greece took its part on Wednesday in the latest widespread strikes against austerity measures that swept across Europe.

In the wake of the meningitis outbreak caused by contaminated compounded medications produced by the New England Compounding Center (NECC).

How can the emerging field of data science help to fruitfully translate research and discovery into successful drug development.

With the Presidential election decided and President Obama the clear winner, it’s time for Pharma to get down to business on the implementation of ObamaCare.

The pharmaceutical industry as of late has faced a growing movement against patent protection in favor of providing access to low cost medicines, specifically in developing countries.

Pharm Exec's 2013 Pipeline Report

Providers and patients fish for that delicate balance between access and abandonment.

Prix Galien celebrates a new round of next generation drug technologies.